Chiusura precedente | 1,1800 |
Aperto | 1,1800 |
Denaro | 0,0000 x 0 |
Lettera | 0,0000 x 0 |
Min-Max giorno | 1,1800 - 1,1800 |
Intervallo di 52 settimane | 0,3900 - 18,0000 |
Volume | |
Media Volume | 4.941 |
Capitalizzazione | 5,596M |
Beta (5 anni mensile) | 3,56 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,4000 |
Prossima data utili | 20 mag 2024 - 24 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Orders and Paid Claims Increasing Since Rollout of Reimbursement CodeFRAMINGHAM, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a commercialization update on the Company’s first product, AC5® Advanced Wound System. Since the Centers for Medicare and Medicaid Services (“CMS”) established A2020, a Level II Healthcare Common Procedure Codi
Common Stock Listing on National Exchange is Next Planned Significant MilestoneFRAMINGHAM, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that it completed a private placement with institutional and accredited individual investors (collectively, the “Investors”) as a Bridge Offering preceding a planned national exchange listing of the
SAWC Spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated AC5 HCPCS reimbursement codeFRAMINGHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company will be exhibiting its AC5® Advanced Wound System (“AC5”) at the Symposium on Advanced Wound Care (“SAWC”) Spring 2023, which ta